• Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy

Browse Tag

psoriasis

Almirall
September 16, 2022
Pharmaceutical News

Almirall:Tildrakizumab is the first and only IL-23p19 inhibitor to demonstrate meaningful sleep improvement in people living with psoriasis

Barcelon, a global biopharmaceutical company focused on skin health, announced at the 31st EADV (European Association of Dermatology and Venereology) Congress the results from TRIBUTE, an interventional phase IV clinical study,  which resembled real-life clinical practice. In this study, Ilumetri®▼ (tildrakizumab) is the first IL-23p19 inhibitor to demonstrate improvement on sleep impairment in patients with moderate-to-severe chronic plaque psoriasis.  At week

More
Almirall
Pharmaceutical News

Almirall:Tildrakizumab is the first and only IL-23p19 inhibitor to demonstrate meaningful sleep improvement in people living with psoriasis

September 16, 2022

Barcelon, a global biopharmaceutical company focused on skin health, announced at the 31st EADV (European Association of Dermatology and Venereology) Congress the results from TRIBUTE,

More
  • Meeting Global Demands for Viral Vector-based Vaccines
  • Croda and Botanical Solution Inc. (BSI) partner to fast-track sustainable vaccine adjuvant QS-21 production
  • Liquid Nitrogen Freezers Prove to be Game Changer for Pharma Industry
  • Breye Therapeutics Strengthens Management Team and Board
  • How Healthcare Professionals Benefit From Field Hospitals

© 2010-2022 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy
Go toTop